vs
Side-by-side financial comparison of Gossamer Bio, Inc. (GOSS) and Maase Inc. (MAAS). Click either name above to swap in a different company.
Gossamer Bio, Inc. is the larger business by last-quarter revenue ($13.8M vs $9.9M, roughly 1.4× Maase Inc.).
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics for patients with serious immunology, inflammation and oncology conditions. It advances a pipeline of proprietary product candidates across multiple clinical phases, primarily serving healthcare markets in North America and other global regions.
GOSS vs MAAS — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2023
| Metric | | |
|---|---|---|
| Revenue | $13.8M | $9.9M |
| Net Profit | $-47.2M | — |
| Gross Margin | — | 78.7% |
| Operating Margin | -333.6% | -55.9% |
| Net Margin | -342.3% | — |
| Revenue YoY | 47.1% | — |
| Net Profit YoY | -43.0% | — |
| EPS (diluted) | $-0.21 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.8M | — | ||
| Q3 25 | $13.3M | — | ||
| Q2 24 | $95.8M | — | ||
| Q1 24 | $0 | — | ||
| Q3 23 | $0 | — | ||
| Q2 23 | $0 | — | ||
| Q4 22 | — | $9.9M |
| Q4 25 | $-47.2M | — | ||
| Q3 25 | $-48.2M | — | ||
| Q2 24 | $49.2M | — | ||
| Q1 24 | $-41.9M | — | ||
| Q3 23 | $-40.0M | — | ||
| Q2 23 | $-42.5M | — | ||
| Q4 22 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q4 22 | — | 78.7% |
| Q4 25 | -333.6% | — | ||
| Q3 25 | -369.4% | — | ||
| Q2 24 | 54.3% | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q4 22 | — | -55.9% |
| Q4 25 | -342.3% | — | ||
| Q3 25 | -362.7% | — | ||
| Q2 24 | 51.4% | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q4 22 | — | — |
| Q4 25 | $-0.21 | — | ||
| Q3 25 | $-0.21 | — | ||
| Q2 24 | $0.22 | — | ||
| Q1 24 | $-0.19 | — | ||
| Q3 23 | $-0.21 | — | ||
| Q2 23 | $-0.45 | — | ||
| Q4 22 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $136.9M | $10.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-122.8M | $31.6M |
| Total Assets | $172.2M | $47.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $136.9M | — | ||
| Q3 25 | $180.2M | — | ||
| Q2 24 | $354.5M | — | ||
| Q1 24 | $244.4M | — | ||
| Q3 23 | $328.9M | — | ||
| Q2 23 | $162.1M | — | ||
| Q4 22 | — | $10.9M |
| Q4 25 | $-122.8M | — | ||
| Q3 25 | $-82.3M | — | ||
| Q2 24 | $81.5M | — | ||
| Q1 24 | $26.7M | — | ||
| Q3 23 | $104.6M | — | ||
| Q2 23 | $-62.8M | — | ||
| Q4 22 | — | $31.6M |
| Q4 25 | $172.2M | — | ||
| Q3 25 | $208.8M | — | ||
| Q2 24 | $373.4M | — | ||
| Q1 24 | $259.4M | — | ||
| Q3 23 | $347.9M | — | ||
| Q2 23 | $181.7M | — | ||
| Q4 22 | — | $47.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.3M | $-18.2M |
| Free Cash FlowOCF − Capex | — | $-18.3M |
| FCF MarginFCF / Revenue | — | -184.4% |
| Capex IntensityCapex / Revenue | 0.0% | 1.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.3M | — | ||
| Q3 25 | $-36.2M | — | ||
| Q2 24 | $116.3M | — | ||
| Q1 24 | $-52.3M | — | ||
| Q3 23 | $-34.5M | — | ||
| Q2 23 | $-38.3M | — | ||
| Q4 22 | — | $-18.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q4 22 | — | $-18.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q4 22 | — | -184.4% |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q4 22 | — | 1.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 24 | 2.36× | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q4 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GOSS
Segment breakdown not available.
MAAS
| Wealth management | $7.8M | 78% |
| Insurance consulting | $1.0M | 10% |
| Other | $975.0K | 10% |
| Asset management | $168.0K | 2% |
